Tajemství vládnutí spočívá totiž v tom, jak spojit víru ve vlastní neomylnost se schopností učit se z minulých chyb.

George Orwell

Výzkum

Doxorubicin encapsulation investigated by capillary electrophoresis with laser-induced fluorescence detection

Anthracyclines belong to the most effective anticancer drugs, whereas doxorubicin (DOX) as one of their main representatives is highly efficient and widely used. This compound was firstly isolated from Streptomyces peucetiusin 1960s [1]. In spite of the high efficiency and decades of the using, the administration of the drug over the cumulative dose 550 mg/m2 of body surface area lead to severe side effects including high risk of cardiomyopathy [2, 3],which usually arises the first year after therapy. Nevertheless, cardiac failures can be identified at smaller doses too. This cardiotoxicity is the main force driving the progress towards less toxic formulations enabling also targeted delivery of the drug [4-10].

Due to the optical properties of DOX as well as its biological activity, this molecule is still a target of numerous investigations [11-13]. The DOX fluorescence in relation to the surrounding conditions such as its concentration, nature of solvent and/or presence of quenchers has been exploited [14]. It is thanks to these fluorescent properties that it is possible to track DOX and its formulations including apoferritin- or liposome-encapsulated forms designed to diminish its toxicity by numerous bioanalytical methods [15]. Encapsulation of DOX to nanoparticles preserves the antitumor activity while reducing to risk of cardiotoxicity and increasing distribution of drug to the tumor site. Nowadays, only one commercially available encapsulated DOX is liposome-DOX, called Myocet. The cumulative dose of DOX was increased to 750 mg/m2 to not reach above mentioned side effects [16].

In our study, the fluorescent behavior of DOX in the presence of various fluorescence quenchers was investigated followed by capillary electrophoretic study of encapsulation of DOX in to the cavity of protein based nanotransporter called apoferritin.

Práce je spojená s projektem CEITEC CZ.1.05/1.1.00/02.0068.

---

Plakáty k výzkumným směrům

• Bakteriální rezistence
• Bakteriofág
• MALDI
• Sekvenovíní

Dokumenty pro VaV aktivity

Výzkumný záměr

— pdf

Hodnocení výzkumných aktivit

Archív

16— 2014
15— 2014
14— 2014
13— 2014
12— 2014
11— 2014
10— 2014
9— 2014
8— 2014
7— 2014
6— 2014
5— 2014
4— 2014
3— 2014
2— 2014
1— 2014
42— 2013
41— 2013
40— 2013
39— 2013
38— 2013
37— 2013
36— 2013
35— 2013
34— 2013
33— 2013
32— 2013
31— 2013
30— 2013
29— 2013
28— 2013
27— 2013
26— 2013
25— 2013
24— 2013
23— 2013
22— 2013
21— 2013
20— 2013
19— 2013
18— 2013
17— 2013
16— 2013
15— 2013
14— 2013